TATX-200 / ImmunoPrecise - LARVOL DELTA

$20 Billion Market Breakthrough: IPA Pioneers High-Impact Antibody Development for Next-Generation ADC Cancer Therapies (Businesswire) - "ImmunoPrecise Antibodies Ltd...is proud to announce a significant breakthrough in its primary cancer research initiatives. This accomplishment not only highlights IPA’s cutting-edge discovery and AI capabilities, but it also strategically places the company in the rapidly growing market for these cancer-combating antibodies, which is projected to reach $20.7 billion by 2028. The TATX-112 program, dedicated to the development of specialized antibodies for cancer treatment, has shown encouraging results, successfully targeting cells that express a protein known as TrkB. This achievement has paved the way for several promising candidates for further development....The TATX-200 program is centered on developing T cell engagers, which boost the body's immune response against tumors."

Commercial • Oncology • Solid Tumor

ImmunoPrecise Subsidiary Signs Material Transfer Agreement with Biotheus (Businesswire) - "ImmunoPrecise Antibodies Ltd...jointly announce that the two parties have entered into a Material Transfer and Evaluation Agreement (MTEA) pertaining to a Talem therapeutic antibody asset for the development of a bispecific therapy against solid tumors. Under this MTEA, Biotheus will obtain the rights to further evaluate the suitability of Talem’s Artificial Intelligence (AI)-enhanced TATX-20 lead candidate for the development of novel bispecific antibodies for the treatment of hypoxic solid tumors....Following the transfer, Biotheus will evaluate the TATX-20 lead candidate."

Licensing / partnership • Oncology • Solid Tumor